Qiagen (NYSE:QGEN) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Qiagen N.V. (NYSE:QGEN) saw unusually-strong trading volume on Tuesday. Approximately 6,199,460 shares changed hands during mid-day trading, an increase of 152% from the previous session’s volume of 2,460,511 shares. The stock last traded at $49.3870 and had previously closed at $46.55.

Wall Street Analysts Forecast Growth

QGEN has been the subject of a number of recent research reports. Kepler Capital Markets set a $38.60 price target on Qiagen and gave the stock a “hold” rating in a research report on Thursday, June 25th. Stifel Nicolaus set a $40.00 target price on Qiagen in a research note on Friday, August 7th. Berenberg Bank set a $45.50 price target on Qiagen and gave the company a “hold” rating in a research note on Tuesday, July 14th. UBS Group started coverage on Qiagen in a report on Wednesday, September 9th. They set a “neutral” rating and a $47.00 target price for the company. Finally, Morgan Stanley restated an “overweight” rating on shares of Qiagen in a research note on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Qiagen currently has an average rating of “Hold” and an average price target of $43.93.

Qiagen Price Performance

The company’s 50-day moving average is $43.88 and its two-hundred day moving average is $40.39. The firm has a market cap of $10.18 billion, a P/E ratio of 25.28, a PEG ratio of 4.59 and a beta of 0.61. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts anticipate that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Qiagen

A number of hedge funds have recently made changes to their positions in the stock. Cordatus Wealth Management LLC bought a new position in Qiagen during the 3rd quarter worth approximately $678,000. Assenagon Asset Management S.A. boosted its stake in shares of Qiagen by 1.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 15,722 shares of the company’s stock valued at $691,000 after purchasing an additional 286 shares during the last quarter. GAMMA Investing LLC bought a new stake in shares of Qiagen in the 3rd quarter valued at $345,000. State Street Corp boosted its stake in shares of Qiagen by 4.5% in the 2nd quarter. State Street Corp now owns 2,183,206 shares of the company’s stock valued at $85,363,000 after purchasing an additional 93,575 shares during the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of Qiagen during the second quarter worth $252,000. 70.00% of the stock is currently owned by institutional investors.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.